Abatacept; placebo; methotrexate
A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00122382/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1052 чел. во всех странах исследования.
- Плановая дата окончания (02.2009) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 6
Критерии включения
- Diagnosis of rheumatoid arthritis (RA) <=2 years; MTX naive or <=10 mg/wk for <=3 weeks. No dose within 3 months prior to informed consent.
- C-Reactive Protein (CRP) >= 4.5 mg/L (after amendment)
- Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive
- Tender joints >=12 and swollen joints >=10
Критерии невключения
- Women and men who are not willing to use birth control
- Diagnosed with other rheumatic disease
- History of cancer within 5 years
- Active tuberculosis
- Treatment with another investigation drug within 28 days
- Active bacterial or viral infection
Источник: ClinicalTrials.gov, NCT00122382 · запись обновлена в реестре 16 ноября 2010.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 15
- Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 — Month 12
- Mean Change From Baseline in Radiographic Total Score to Month 12 — Baseline, Month 12
- Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period — Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
- Number of Participants With Serious Adverse Events Reported During the Open-Label Period — Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
- Number of Participants With SAEs With an Outcome of Death During the Open-label Period — Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
- Incidence Rates of Autoimmune Disorders in ABA-Treated Participants — Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first).
- Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants — Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
- Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants — Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
- Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period — Open-Label Period (Month 12 to Month 24)
- Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period — Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Цель исследования
This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00122382 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.